5 Key Takeaways
-
1
A post hoc analysis of the HELIOS trial indicates that OTX-TKI may reduce retinal leakage for up to 12 months in diabetic retinopathy patients.
-
2
The analysis utilized ultra-widefield fluorescein angiography to measure changes in retinal leakage over time.
-
3
Patients treated with OTX-TKI showed a decrease in leakage area and index, contrasting with the sham group, which exhibited increased leakage.
-
4
OTX-TKI is a bioresorbable implant that releases axitinib, a tyrosine kinase inhibitor, over 6 to 12 months.
-
5
The findings suggest OTX-TKI may serve as a long-acting treatment option for diabetic retinopathy, pending further studies.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.